Pharmacological vitreolysis
AssigneeThromboGenics NV
InventorsSteve Pakola, Marc De Smet
Life of this patent
Estimating the term…
Loading patent…
AssigneeThromboGenics NV
InventorsSteve Pakola, Marc De Smet
Estimating the term…
A method of treating or preventing a disorder, or a complication of a disorder, of an eye of a subject comprising contacting a vitreous and/or aqueous humor with a composition comprising a truncated form of plasmin comprising a catalytic domain of plasmin (TPCD). TPCDs include, but are not limited to, miniplasmin, microplasmin and derivatives and variants thereof. The methods of the invention can be used to reduce the viscosity of the vitreous, liquefy the vitreous, induce posterior vitreous detachment, reduce hemorrhagic blood from the eye, clear or reduce materials toxic to the eye, clear or reduce intraocular foreign substances from the eye, increase diffusion of a composition administered to an eye, reduce extraretinal neovascularization and any combinations thereof. The method can be used in the absence of, or as an adjunct to, vitrectomy.
A method of increasing diffusion of an agent administered to the vitreous of an eye of a subject, comprising contacting the vitreous with a microplasmin prior to or concomitant with contacting the vitreous with the agent, wherein the method results in increasing diffusion of the agent in the vitreous of the eye of the subject.
Dependencies are inferred from the claim text.